- Home
- CLPT vs PWRL Comparison
CLPT vs PWRL Comparison
Compare CLPT & PWRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLPT | PWRL |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.9M | 523.7M |
| IPO Year | 2009 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CLPT | PWRL |
|---|---|---|
| Price | $16.82 | $11.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | ★ 571.2K | 122.3K |
| Earning Date | 05-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,971,000.00 | N/A |
| Revenue This Year | $45.67 | N/A |
| Revenue Next Year | $19.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.78 | N/A |
| 52 Week Low | $8.27 | $10.21 |
| 52 Week High | $30.10 | $16.31 |
Technical Indicators
Market Signals| Indicator | CLPT | PWRL |
|---|---|---|
| Relative Strength Index (RSI) | 53.10 | 40.03 |
| Support Level | $13.25 | $10.21 |
| Resistance Level | $16.54 | $12.35 |
| Average True Range (ATR) | 0.56 | 0.61 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 80.87 | 40.64 |
Price Performance
Historical ComparisonAbout CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
About PWRL Powerlaw Corp. Common Stock
Powerlaw Corp is a non-diversified, closed-end management investment company. The Fund's investment objective is long-term capital appreciation. It seeks to achieve its investment objective by investing in the equity and equity-linked securities of a concentrated portfolio of approximately 12 to 15 late-stage technology companies.